文献速递消化系统肿瘤

利用常规计算机断层扫描预测转移性结直肠癌结局的影像特征

An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans.
PubMed 文献 · Eur J Cancer · 2021-12-13

研究回顾性分析两项III期试验中1584例转移性结直肠癌患者的CT图像,在训练集(n=720)中训练算法预测总生存期,在验证集(n=864)中以RECIST1.1为基准评估特征与OS的关联。影像特征结合肿瘤体积变化、空间异质性变化和肿瘤体积三项特征,较RECIST1.1显示出更强的预后区分能力。

要点

  • 影像特征在验证集中风险比为21.04(14.88-30.58),高于RECIST1.1的3.93(2.79-5.54)。
  • RECIST1.1判定的稳定疾病患者可被影像特征重新分类,最有利与最不利四分位中位OS分别为40.73个月和7.03个月。
  • 该特征可提供早期预后信息,可能改善个体化治疗决策和临床试验分析。

核心结论

  • 结合三项影像特征的特征值可提供早期预后信息,可能改善个体患者的治疗决策和临床试验分析。

研究设计与样本

  • 回顾性分析两项III期试验中1584例转移性结直肠癌患者的CT图像,训练集720例,验证集864例。
  • 两项III期试验分别评估FOLFOX±帕尼单抗(n=331,350)和FOLFIRI±阿柏西普(n=437,466)。

主要发现

  • 训练集选出的特征结合肿瘤体积变化、肿瘤空间异质性变化和肿瘤体积三项特征预测总生存期。
  • 验证集中RECIST1.1将患者分为缓解166例(19.2%)、稳定疾病636例(73.6%)和进展62例(7.2%),风险比为3.93(2.79-5.54)。
  • 采用相同分布,影像特征的风险比为21.04(14.88-30.58),显示增量预后分离。
  • RECIST1.1判定的稳定疾病被影像特征沿连续谱重新分类,最有利四分位患者中位OS为40.73(28.49至未达到)个月(n=94),最不利四分位为7.03(5.66-7.89)个月(n=166)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Quantitative analysis of computed tomography (CT) scans of patients with metastatic colorectal cancer (mCRC) can identify imaging signatures that predict overall survival (OS). METHODS: We retrospectively analysed CT images from 1584 mCRC patients on two phase III trials evaluating FOLFOX ± panitumumab (n = 331, 350) and FOLFIRI ± aflibercept (n = 437, 466). In the training set (n = 720), an algorithm was trained to predict OS landmarked from month 2; the output was a signature value on a scale from 0 to 1 (most to least favourable predicted OS). In the validation set (n = 864), hazard ratios (HRs) evaluated the association of the signature with OS using RECIST1.1 as a benchmark of comparison. RESULTS: In the training set, the selected signature combined three features - change in tumour volume, change in tumour spatial heterogeneity, and tumour volume - to predict OS. In the validation set, RECIST1.1 classified patients in three categories: response (n = 166, 19.2%), stable disease (n = 636, 73.6%), and progression (n = 62, 7.2%). The HR was 3.93 (2.79-5.54). Using the same distribution for the signature, the HR was 21.04 (14.88-30.58), showing an incremental prognostic separation. Stable disease by RECIST1.1 was reclassified by the signature along a continuum where patients belonging to the most and least favourable signature quartiles had a median OS of 40.73 (28.49 to NA) months (n = 94) and 7.03 (5.66-7.89) months (n = 166), respectively. CONCLUSIONS: A signature combining three imaging features provides early prognostic information that can improve treatment decisions for individual patients and clinical trial analyses.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Dercle L, Zhao B, Gönen M, et al. An imaging signature to predict outcome in metastatic colorectal cancer using routine computed tomography scans. Eur J Cancer. 2021. PMID: 34916122. doi:10.1016/j.ejca.2021.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。